ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 628

Longitudinal Changes in Relative Market Share Proportions of Biologic and Targeted Synthetic Disease-Modifying Anti-Rheumatic Drugs for Treatment of Rheumatoid Arthritis: Descriptive Data from the Ontario Best-Practice Research Initiative Database

Elliot Hepworth1, Mohammad Movahedi2, Emmanouil Rampakakis3, Reza Mirza1, Arthur Lau4, Angela Cesta5, Janet E. Pope6 and Claire Bombardier7, 1Department of Internal Medicine, McMaster University, Hamilton, ON, Canada, 2JSS Medical Research, St-Laurent, QC, Canada, 3JSS Medical Research, Montreal, QC, Canada, 450 Charlton Avenue East, St Joseph's Healthcare Hamilton, Hamilton, ON, Canada, 5Ontario Best Practices Research Initiative, University Health Network, Toronto, ON, Canada, 6Department of Medicine, University of Western Ontario, London, ON, Canada, 7Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Biologics, mechanisms, registry, rheumatoid arthritis, treatment and small molecules

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: Rheumatoid Arthritis – Treatments Poster I: Strategy and Epidemiology

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: For patients with Rheumatoid Arthritis (RA) who do not achieve adequate clinical response with combined conventional synthetic disease modifying anti-rheumatic drugs (csDMARDs), the next step in goal-directed therapy is initiation of either biologic DMARDs (bDMARDs) or targeted synthetic DMARDs (tsDMARDs). bDMARDs include tumour-necrosis factor inhibitors (TNFi) or non-TNFi classes. Since inception of Ontario Best Practice Research Initiative (OBRI), new treatment options have become available. We aimed to describe the evolution of relative use of non-TNFi vs. TNFi in Ontario-based practices from 2008-2017.

Methods: Adult patients with RA enrolled in the OBRI who started therapy with bDMARDs or tsDMARDs anytime during, or up to 30 days before, enrollment were included. Using descriptive analysis of data from each year between 2008 and 2017, the relative proportion of the population treated with TNFi and non-TNFi therapy was measured for (i) all patients and (ii) those initiating their first bDMARD/tsDMARD. TNFi included: Etanercept, Adalimumab, Certolizumab, Golimumab, and Infliximab. Non-TNFi included: Abatacept, Rituximab, Tocilizumab, and Tofacitinib.

Results: A total of 1,057 patients were included of whom 653 were bDMARD/tsDMARD na•ve. In 2008, the relative non-TNFi use was 3/56 (5.4%) in all patients and 0/31 (0%) in treatment-na•ve patients. By 2013 the proportion non-TNFi use increased to 135/562 (24%) in all patients and 11/92 (12.0%) in treatment-na•ve patients. This increasing trend in relative non-TNFi utilization continued in both groups until 2016 when relative use was 224/679 (33.0%) in all patients and 17/56 (30.4%) in treatment-na•ve. This was followed by 144/426 (33.8%) and 4/15 (26.7%), respectively in 2017.

Conclusion: This descriptive analysis of data from the OBRI cohort shows an increase in the use of non-TNFi therapies. The overall trend towards greater use of non-TNFi therapies as first line agents after combined csDMARDs may be partially explained by the presence of guidelines that allow clinicians to select any of the above options as first line advanced therapies. Future analyses evaluating patient-, disease- and concomitant drug use-specific determinants of physician decision-making will be conducted.

 

 

Figure 1: Proportion of biologic use according to mechanism of action by calendar year (n=1057)

Figure 2: Proportion of first biologic use in biologic na•ve patients according to mechanism of action by time period (n=653)

 


Disclosure: E. Hepworth, None; M. Movahedi, None; E. Rampakakis, JSS Medical Research, 3; R. Mirza, None; A. Lau, AbbVie Inc., 8, 9,Amgen Inc., 8, 9,BMS, 8, 9,Celgene Corporation, 8, 9,Eli Lilly and Co., 8, 9,Merck & Co., 8, 9,Novartis, 8, 9,Janssen, 8, 9,Pfizer, Inc., 8, 9,Roche, 8, 9,Sanofi, 8, 9,Genzyme, 8, 9,UCB, Inc., 8, 9; A. Cesta, None; J. E. Pope, AbbVie Inc., 5,Amgen Inc., 5,Bristol-Myers Squibb, 5,Lilly, 5,Merck & Co., 5,Novartis, 5,Pfizer, Inc., 5,Roche, 5,Sanofi, 5,Sandoz, 5,Celltrion, 5,United Chemicals Belgium, 2; C. Bombardier, Canada Research chair in Knowledge Transfer for Musculotoskeletal Care, 6,Pfizer Research Chair in Rheumatology, 6.

To cite this abstract in AMA style:

Hepworth E, Movahedi M, Rampakakis E, Mirza R, Lau A, Cesta A, Pope JE, Bombardier C. Longitudinal Changes in Relative Market Share Proportions of Biologic and Targeted Synthetic Disease-Modifying Anti-Rheumatic Drugs for Treatment of Rheumatoid Arthritis: Descriptive Data from the Ontario Best-Practice Research Initiative Database [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/longitudinal-changes-in-relative-market-share-proportions-of-biologic-and-targeted-synthetic-disease-modifying-anti-rheumatic-drugs-for-treatment-of-rheumatoid-arthritis-descriptive-data-from-the-ont/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/longitudinal-changes-in-relative-market-share-proportions-of-biologic-and-targeted-synthetic-disease-modifying-anti-rheumatic-drugs-for-treatment-of-rheumatoid-arthritis-descriptive-data-from-the-ont/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology